Niemann-Pick Disease Niemann-Pick Type C Disease— Pathophysiology and Future Perspectives for Treatment Cristin D Davidson1 and Steven U Walkley, DVM, PhD2 1. Graduate Student; 2. Professor, Department of Neuroscience, Pathology, and Neurology, Albert Einstein College of Medicine
Abstract
Niemann-Pick type C (NPC) disease is a rare and fatal inherited metabolic disorder that results in intracellular accumulation of cholesterol and glycolipids within the endosomal/lysosomal system. Central nervous system (CNS) involvement is especially prominent as evidenced by ataxia and progressive decline of motor skills and intellectual function. Defects in either the NPC1 or NPC2 protein, both of which are thought to be involved in the egress of cholesterol and other lipids out of the endosomal/lysosomal system, leads to NPC disease. The pathogenic cascade is not well understood, and currently there is no corrective therapy for NPC patients. However, some compounds tested in animal models of NPC disease have shown promise in slowing disease onset and progression, and administration of these drugs in combination has provided evidence of synergy and enhanced clinical benefit. This favorable outcome indicates that combinatorial therapies using small molecules likely represent the best therapeutic option available to NPC patients at this time.
Keywords Cholesterol, glycosphingolipids, combination therapy, cyclodextrin, miglustat, lysosomal disease
Disclosure: Cristin D Davison has no conflicts of interest to declare. Steven U Walkley, DVM, PhD, is an author on a patent for the use of miglustat in the treatment of Niemann- Pick type C.
Acknowledgments: The authors would like to thank the National Institutes of Health (NIH NS053677), Dana’s Angels Research Trust (DART), and the Ara Parseghian Medical Research Foundation for support and gratefully acknowledge collaborative interactions with Dr D Ory, Dr Y Ioannou, and Dr F Platt. Received: May 9, 2010 Accepted: June 28, 2010 Citation: US Neurology, 2010;6(1):88–94 Correspondence: Steven U Walkley, DVM, PhD, Department of Neuroscience, Pathology, and Neurology, Albert Einstein College of Medicine, 1410 Pelham Parkway, Kennedy 618, Bronx, NY 10461. E:
steve.walkley@einstein.yu.edu
Lysosomal diseases are rare metabolic disorders that result from inherited defects in the endosomal/lysosomal system and often lead to severe clinical disease and premature death. The endosomal/ lysosomal system is a vital recycling center that plays a critical role in intracellular signaling and homeostatic events, including a primary role in the breakdown and salvage of most cellular components. Endosomal/lysosomal dysfunction leads to a complex disease cascade, with the most recognizable feature being the intracellular accumulation of unmetabolized products. Since the precise role of the lysosomal system is not the same in cells with different metabolic signatures, the overall pathologic features typically vary by both disease and cell type. In approximately two-thirds of lysosomal diseases there is significant central nervous system (CNS) involvement. Niemann-Pick Type C (NPC) disease is one such lysosomal disorder and is characterized by prominent intracellular accumulation of unesterified cholesterol and several glycosphingolipids (GSLs).1,2
While many cell types are affected in NPC
disease, the storage of unmetabolized products is especially severe in cells of the CNS and leads to a variety of pathologic changes and to neuronal dysfunction. Intraneuronal storage is accompanied by many other well-known pathologic changes, including the formation of
88
meganeurites, the growth of ectopic dendrites, and the widespread occurrence of neuroaxonal dystrophy.3
Patients with NPC disease
typically present with vertical supranuclear gaze palsy (VSGP) and learning difficulties, followed by ataxia, seizures, dystonia, respiratory dysfunction, and progressive mental decline.1,4–6
Most patients
succumb to NPC disease in adolescence, although disease onset is variable and adult-onset cases of NPC disease have been reported.7
Niemann-Pick Type C Disease—A Brief History The discovery of Niemann-Pick disease is attributed to Albert Niemann, a German pediatrician, and Ludwig Pick, a German pathologist. In 1914, Niemann provided a report of a child with CNS impairment and enlarged liver and spleen (hepatosplenomegaly).8 Several years later in the 1920s, Pick analyzed tissues from children with these clinical signs and established this as a new, distinct disease. Niemann-Pick disease was subsequently separated into four different types (A, B, C, and D) by Crocker in the late 1950s based on varying clinical and biochemical data.9
Subsequently, it was shown
that Niemann-Pick types A and B (NPA and NPB) are caused by mutations in the SMPD1 gene, which codes for acid sphingomyelinase and, when deficient, leads to intracellular accumulation of
© TOUCH BRIEFINGS 2010
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108